Medico-economic Evaluation of Robot-assisted Laparoscopy Compared With Conventional Laparoscopy in Hysterectomy for Endometrial Cancer.
Conditions: Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma Interventions: Procedure: Robot-assisted laparoscopy; Procedure: conventional laparoscopy; Other: Prospective cohort study; Other: Retrospective cohort study; Other: information and consent; Other: randomization; Other: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence; Other: Surgical data collection; Other: Biological data collection; Other: Collection of histological data from the surgical specimen; Other: Phone calls; Other: Pain assessment; Other: Collect of data on non...
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
Conditions: Breast Carcinoma; Breast Ductal Carcinoma in Situ Interventions: Behavioral: Patient Navigatrion; Other: Questionnaire Sponsors: Roswell Park Cancer Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Conditions: Hepatocellular Carcinoma Interventions: Combination Product: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib Sponsors: Yongyi Zeng Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
The Study is Being Conducted to to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of Serplulimab Injection (HLX10) and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Conditions: Carcinoma, Hepatocellular Interventions: Drug: HLX53 (1000mg); Drug: HLX53 (2000mg); Drug: HLX10; Drug: HLX04; Other: Placebo Sponsors: Shanghai Henlius Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
Conditions: Carcinoma, Hepatocellular Interventions: Drug: HLX53 (1000mg); Drug: HLX53 (2000mg); Drug: HLX10; Drug: HLX04; Other: Placebo Sponsors: Shanghai Henlius Biotech Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
Conditions: Salivary Gland Neoplasm Duct Interventions: Drug: Rezvilutamide; Drug: Leuprolide Acetate Sponsors: Peking University First Hospital; Jiangsu Hengrui Pharmaceutical Co., Ltd.; Beijing Biote Pharmaceutical Co.,Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine
Conditions: Prostate Adenocarcinoma; Prostate Carcinoma Interventions: Other: Non-Interventional Study Sponsors: Mayo Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer Interventions: Drug: Trastuzumab emtansine; Drug: Pertuzumab Injection; Drug: Docetaxel; Drug: Tamoxifen; Drug: Letrozole; Drug: Goserelin Sponsors: University of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Massive Nasal Bleeding in Patients With NPC Received Curative RT
Conditions: Nasopharyngeal Carcinoma Patients Treated With Curative Radiotherapy Interventions: Other: Patients without massive nasal bleeding; Other: Patients with massive nasal bleeding Sponsors: Taichung Veterans General Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 4, 2024 Category: Research Source Type: clinical trials
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
Conditions: Advanced Renal Cell Carcinoma (aRCC) Interventions: Combination Product: Nivolumab + Ipilimumab combination therapy; Combination Product: Pembrolizumab + Lenvatinib combination therapy Sponsors: Bristol-Myers Squibb Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
To Assess the Safety and Efficacy of SP-002 With Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
Conditions: Basal Cell Carcinoma Interventions: Drug: SP-002; Drug: Vismodegib Sponsors: Stamford Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Early Detection of Liver Cancer by QUS
Conditions: Hepatocellular Carcinoma; Liver Cancer Interventions: Diagnostic Test: Quantitative Ultrasound; Diagnostic Test: B-mode Ultrasound; Diagnostic Test: Magnetic Resonance Imaging; Diagnostic Test: Liver Biopsy Sponsors: Centre hospitalier de l ' Universit é de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l ' Universit é de Montréal; Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer
Conditions: Hepatocellular Carcinoma (HCC) Interventions: Drug: BAY3630942; Drug: BAY3547922 Sponsors: Bayer Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
Conditions: Bladder Cancer; Muscle-Invasive Bladder Carcinoma Interventions: Drug: DisitamabVedotinForIicction Toripalimab Sponsors: Zhujiang Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Dermatoscopy Guided Resection for Skin Cancer
Conditions: Basal Cell Carcinoma; Cutaneous Squamous Cell Carcinoma; Surgical Margin Interventions: Device: Dermatoscopy Sponsors: Region Örebro County Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
